{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:06:30Z","timestamp":1775279190551,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,8,3]],"date-time":"2013-08-03T00:00:00Z","timestamp":1375488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00280-013-2241-7","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T21:22:54Z","timestamp":1375392174000},"page":"653-660","source":"Crossref","is-referenced-by-count":6,"title":["Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer"],"prefix":"10.1007","volume":"72","author":[{"given":"Taejong","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chel Hun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Joong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung-Gie","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duk Soo","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,3]]},"reference":[{"key":"2241_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/1098-2388(200007\/08)19:1<11::AID-SSU3>3.0.CO;2-3","volume":"19","author":"DE Marsden","year":"2000","unstructured":"Marsden DE, Friedlander M, Hacker NF (2000) Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 19:11\u201319","journal-title":"Semin Surg Oncol"},{"key":"2241_CR2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.1995.13.7.1584","volume":"13","author":"J Kavanagh","year":"1995","unstructured":"Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzalez de Leon C, Fishman A, Mante R, Hord M, Kudelka A (1995) Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13:1584\u20131588","journal-title":"J Clin Oncol"},{"key":"2241_CR3","first-page":"837","volume":"2","author":"JJ Kavanagh","year":"1996","unstructured":"Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen P, Edwards CL, Freedman RS, Verschraegen CF (1996) Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2:837\u2013842","journal-title":"Clin Cancer Res"},{"key":"2241_CR4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389\u2013393","journal-title":"J Clin Oncol"},{"key":"2241_CR5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","volume":"15","author":"FM Muggia","year":"1997","unstructured":"Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987\u2013993","journal-title":"J Clin Oncol"},{"key":"2241_CR6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","volume":"63","author":"JD Shapiro","year":"1996","unstructured":"Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC (1996) Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63:89\u201393","journal-title":"Gynecol Oncol"},{"key":"2241_CR7","first-page":"188","volume":"17","author":"D Tresukosol","year":"1996","unstructured":"Tresukosol D, Kudelka AP, Gonzales de Leon C, Edwards CL, Freedman RS, Mante R, Hord M, Kavanagh JJ (1996) Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Eur J Gynaecol Oncol 17:188\u2013191","journal-title":"Eur J Gynaecol Oncol"},{"key":"2241_CR8","first-page":"47","volume":"6","author":"T Dorval","year":"1996","unstructured":"Dorval T, Soussain C, Beuzeboc P, Garcia-Giralt E, Jouve M, Livartowski A, Mosseri V, Palangie T, Scholl S, Sastre X, Pouillart P (1996) Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. J Infus Chemother 6:47\u201349","journal-title":"J Infus Chemother"},{"key":"2241_CR9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/gyno.1998.5065","volume":"70","author":"M Markman","year":"1998","unstructured":"Markman M, Kennedy A, Sutton G, Hurteau J, Webster K, Peterson G, Kulp B, Belinson J (1998) Phase 2 trial of single agent ifosfamide\/mesna in patients with platinum\/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 70:272\u2013274","journal-title":"Gynecol Oncol"},{"key":"2241_CR10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/030089169908500401","volume":"85","author":"G Scarfone","year":"1999","unstructured":"Scarfone G, Villa A, Parazzini F, Sciatta C, Polverino G, Bolis G (1999) A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and\/or paclitaxel-containing chemotherapy. Tumori 85:217\u2013219","journal-title":"Tumori"},{"key":"2241_CR11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.COC.0000054896.56416.79","volume":"27","author":"M Shaheen","year":"2004","unstructured":"Shaheen M, Stender MJ, McClean JW, Look KY, Einhorn LH (2004) Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study. Am J Clin Oncol 27:229\u2013231","journal-title":"Am J Clin Oncol"},{"key":"2241_CR12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ygyno.2004.01.027","volume":"93","author":"S Chiara","year":"2004","unstructured":"Chiara S, Tognoni A, Pastrone I, Tomasello L, Brema F, Di Costanzo G, Folco U, Pronzato P (2004) Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecol Oncol 93:474\u2013478","journal-title":"Gynecol Oncol"},{"key":"2241_CR13","first-page":"1028","volume":"87","author":"A Salar","year":"2002","unstructured":"Salar A, Martino R, Perea G, Ribera JM, Lopez-Guillermo A, Guardia R, Escoda L, Altes A, Sierra J, Montserrat E (2002) High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin\u2019s lymphoma. Haematologica 87:1028\u20131035","journal-title":"Haematologica"},{"key":"2241_CR14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2009.09.036","volume":"116","author":"F Joly","year":"2010","unstructured":"Joly F, Sevin E, Lortholary A, Priou F, Paitel JF, Fabbro M, Henry-Amar M, Hamond K, Bourgeois H (2010) Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial. Gynecol Oncol 116:312\u2013316","journal-title":"Gynecol Oncol"},{"key":"2241_CR15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1525-1438.2006.00288.x","volume":"16","author":"F Joly","year":"2006","unstructured":"Joly F, Bourgeois H, Floquet A, Chinet-Charrot P, Meyer F, Lebrun D, Hamond K, Leroy C, Heron JF (2006) Efficacy and tolerability of the ifosfamide\u2013epirubicin combination in relapsed ovarian cancer. Int J Gynecol Cancer 16:77\u201382","journal-title":"Int J Gynecol Cancer"},{"key":"2241_CR16","first-page":"8","volume":"27","author":"U Vanhoefer","year":"2000","unstructured":"Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A (2000) Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic. Semin Oncol 27:8\u201313","journal-title":"Semin Oncol"},{"key":"2241_CR17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1179\/joc.1999.11.2.144","volume":"11","author":"A Polyzos","year":"1999","unstructured":"Polyzos A, Tsavaris N, Kosmas C, Petrikos G, Giannikos L, Kalahanis N, Papadopoulos O, Christodoulou K, Giannakopoulos K, Veslemes M, Katsilambros N (1999) Second-line chemotherapy with cisplatin\u2013ifosfamide in patients with ovarian cancer previously treated with carboplatin\u2013cyclophosphamide. J Chemother 11:144\u2013149","journal-title":"J Chemother"},{"key":"2241_CR18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/02841869509093965","volume":"34","author":"JC Cervellino","year":"1995","unstructured":"Cervellino JC, Araujo CE, Sanchez O, Miles H, Nishihama A (1995) Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. Acta Oncol 34:257\u2013259","journal-title":"Acta Oncol"},{"key":"2241_CR19","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1200\/JCO.2002.07.045","volume":"20","author":"JD Bloss","year":"2002","unstructured":"Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J (2002) Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 20:1832\u20131837","journal-title":"J Clin Oncol"},{"key":"2241_CR20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ygyno.2006.12.023","volume":"105","author":"DR Crotzer","year":"2007","unstructured":"Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C (2007) A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 105:399\u2013403","journal-title":"Gynecol Oncol"},{"key":"2241_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2241_CR22","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1200\/JCO.2004.10.028","volume":"22","author":"B Gronlund","year":"2004","unstructured":"Gronlund B, H\u00f8gdall C, Hilden J, Engelholm SA, H\u00f8gdall EV, Hansen HH (2004) Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 22:4051\u20134058","journal-title":"J Clin Oncol"},{"key":"2241_CR23","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","volume":"21","author":"GJ Rustin","year":"2003","unstructured":"Rustin GJ (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21:187s\u2013193s","journal-title":"J Clin Oncol"},{"key":"2241_CR24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/07357900500449595","volume":"24","author":"M Baur","year":"2006","unstructured":"Baur M, Fazeny-Doerner B, Hudec M, Sevelda P, Salzer H, Dittrich C (2006) Ifosfamide\/mesna as salvage therapy in platinum pretreated ovarian cancer patients\u2014long-term results of a phase II study. Cancer Invest 24:22\u201327","journal-title":"Cancer Invest"},{"key":"2241_CR25","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1200\/JCO.1989.7.11.1672","volume":"7","author":"GP Sutton","year":"1989","unstructured":"Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J (1989) Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 7:1672\u20131676","journal-title":"J Clin Oncol"},{"key":"2241_CR26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/gyno.1995.1012","volume":"56","author":"P Sorensen","year":"1995","unstructured":"Sorensen P, Pfeiffer P, Bertelsen K (1995) A phase 2 trial of ifosfamide\/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 56:75\u201378","journal-title":"Gynecol Oncol"},{"key":"2241_CR27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1006\/gyno.2001.6508","volume":"84","author":"A Gonzalez-Martin","year":"2002","unstructured":"Gonzalez-Martin A, Crespo C, Garcia-Lopez JL, Pedraza M, Garrido P, Lastra E, Moyano A (2002) Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen. Gynecol Oncol 84:368\u2013373","journal-title":"Gynecol Oncol"},{"key":"2241_CR28","first-page":"1645","volume":"27","author":"A Polyzos","year":"2007","unstructured":"Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A (2007) Paclitaxel\u2013ifosfamide\u2013cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Anticancer Res 27:1645\u20131651","journal-title":"Anticancer Res"},{"key":"2241_CR29","first-page":"2681","volume":"29","author":"A Polyzos","year":"2009","unstructured":"Polyzos A, Tsavaris N, Gogas H, Lagadas A, Polyzos K, Giannakopoulos K, Felekouras E, Tsigris C, Karatzas T, Papadopoulos O, Giannopoulos A (2009) Cisplatin\u2013Ifosfamide\u2013gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel. Anticancer Res 29:2681\u20132686","journal-title":"Anticancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2241-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2241-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T03:20:05Z","timestamp":1563592805000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2241-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["2241"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2241-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,3]]}}}